General
Every effort has been made to ensure the information included on this Web site is true and correct at the time of publication. However, the products and or services described herein are subject to continuous development and improvement, and the right is reserved to change their specifications at any time.
Trademarks
SIMPathways, APOK-DYN, are trademarks or registered trademarks of Helios Biosciences sarl. All other trademarks contained herein are the property of their respective holders.
Links to other web sites
This Web site may contain links to other Web sites which are not under the control of and are not maintained by Helios Biosciences. Helios Biosciences is not responsible for the content of those sites. Helios Biosciences provides these links only as a convenience, and the inclusion of any link to such sites does not imply endorsement by Helios Biosciences of those sites. Helios Biosciences reserves the right to terminate any link or linking program at any time.
Meet us in Washington during BIO 2011. Visit us on our booth (hosted by the competitiveness bio-cluster Medicen) , request a meeting during the Bio Business Forum or attend the Fast-Track session organized by the French competitiveness clusters.
A publication describing our technology and its use in an european community founded program (FP6: VALAPODYN): Pubmed 20459389.
May 2010
BIO 2010 :
After attending BIoEurope Spring, we will attend BIO 2010 in Chicago. We will be happy to meet you at the French Pavillion (#3712) or during the Bio Business Forum.
March 2010
Immunosupressive drug targets :
We have finalized the experimental validation of 3 of the 6 immunosupressive targets that we have selected. This confirms the immunosuppressive potential of these targets.
Testimonies warmly recommend resorting to Helios BioSciences for any operation of mRNA detection in the brain as well as in other tissues. Their professionalism, their know-how, their dynamism, their customer care and adaptability make them now indispensable collaborators."
Bruno Giros, PhD, Director of the INSERM Research Department U-513, "Neurobiology and Psychiatry"
The primary roadblock in exploring neuromuscular junctions is their relatively small size (~50nm). Helios has certainly shown that is capable of overcoming barriers and exploring new grounds in science through dedications and persistence."
Javad Nazarian, M.S., The Children's National Medical Center, Washington DC.
